GHK-Cu injectable vs topical — what the research literature shows
GHK-Cu (glycyl-L-histidyl-L-lysyl copper(II)) is the same molecule regardless of route — but injectable and topical applications target different research contexts and tissues. Topical GHK-Cu (cosmetic creams, serums) targets dermal fibroblasts and keratinocytes locally with minimal systemic absorption — the dominant published literature is on collagen synthesis stimulation, wound healing, and antioxidant effects in skin. Injectable (SC) GHK-Cu produces systemic exposure with effects across multiple tissues — the literature is more limited but includes hair growth, lung-protective, and broader gene-expression-modulation research. The two routes serve different research questions.
Side-by-side
| GHK-Cu 100 mg | GHK-Cu topical formulations | |
|---|---|---|
| Molecule | GHK-Cu (identical) | GHK-Cu (identical) |
| Route | Subcutaneous injection | Topical (cream/serum) |
| Systemic exposure | Yes | Minimal |
| Primary research focus | Hair growth, lung protection, multi-tissue effects | Skin: collagen, wound healing, antioxidant |
| Concentration in research | ~1-2 mg SC daily | 0.05-2% formulations |
| Research evidence base | Smaller — animal-model and small human trials | Larger — extensive cosmetic dermatology literature |
| Cost per use | Higher per dose | Lower per application |
What to know
- ·Same molecule — receptor / cellular pharmacology is identical regardless of route.
- ·Topical research is the dominant literature base (Pickart, Margolina, others) and informs cosmetic-ingredient claims.
- ·Injectable research is smaller but extends GHK-Cu effects beyond skin to systemic tissues.
- ·Topical is regulated as a cosmetic ingredient; injectable is research-use only.
- ·Combined / sequential protocols (topical for skin, injectable for systemic) are a research-context approach, not a clinical recommendation.
Where the literature diverges
Topical GHK-Cu has decades of cosmetic dermatology research demonstrating collagen synthesis, wound healing, and hair-cycle effects. Injectable GHK-Cu has emerged later from Pickart's broader gene-expression work showing GHK-Cu modulates ~4,000 human genes — the systemic-exposure context is necessary to test those effects in tissues other than skin.
FAQ
Should I do both?+
Different research questions, different tissue targets. Topical for direct dermal effects, SC for systemic. Combining them is research-context only and not a clinical protocol.
Why is topical GHK-Cu in so many cosmetics?+
Long-standing cosmetic-ingredient track record + published literature supporting collagen stimulation + relatively low cost per formulation. INCI name is 'Copper Tripeptide-1' — look for it on ingredient lists rather than vague 'copper peptides' marketing.
This is a research-context comparison of compound mechanism and published trial outcomes. Not medical advice. Both compounds are research-use only when sold by Omega Grade — for in vitro laboratory investigation, not human or veterinary administration.
- ResearchGHK-Cu 100 mg
Copper-bound tripeptide. Deep-blue lyophilised cake — the visual signature of intact Cu²⁺ coordination.
- ResearchGHK-Cu 150 mg pen
High-dose GHK-Cu pen from Astranordic. 1.5× the dose of the standard 100 mg vial, in a pre-filled research pen.
- ResearchGlow Blend 70 mg
ChemAesthetic's multi-peptide dermal blend. Combines GHK-Cu with complementary signalling peptides commonly co-studied in dermal-regeneration research
- Biomarkerhs-CRP 2.5 mg/L
High-sensitivity C-reactive protein at 2.5 mg/L sits in the 'intermediate cardiovascular risk' category most cardiology research uses. What it measures, what drives it, and how to interpret your number.
- ComparisonGHK-Cu vs generic "copper peptides" — what's actually in the bottle
Most products marketed as "copper peptides" contain GHK-Cu specifically — but not all. The research literature on GHK-Cu is far ahead of any other copper-peptide complex.